SCHEMBL23848263

SCHEMBL23848263

COC(=O)c1ccc(F)cc1CCc1cccc(F)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G2A P14555 1/20 0.50
MRGPRX4 Q96LA9 1/20 0.46
FFAR4 Q5NUL3 1/20 0.45
TAAR1 Q96RJ0 1/20 0.45
MAOB P27338 3/20 0.45
MAOA P21397 2/20 0.45
CYP4F2 P78329 1/20 0.44
CYP4A11 Q02928 1/20 0.44
KDM4E B2RXH2 2/20 0.44
GAA P10253 1/20 0.44
STAT1 P42224 1/20 0.44
RAB9A P51151 1/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
ALDH1A1 P00352 1/20 0.44
HPGD P15428 1/20 0.44
MAPK1 P28482 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
HSD17B10 Q99714 1/20 0.44
NR3C2 P08235 1/20 0.43
MAPT P10636 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1743863 0.90 PLA2G2A (0.60) PLA2G2AFFAR4TAAR1KDM4ERAB9A
SCHEMBL1741537 0.80 PLA2G2A (0.52) PLA2G2AMRGPRX4FFAR4ALDH1A1SMN1; SMN2
SCHEMBL12489097 0.79 FFAR4 (0.47) PLA2G2AFFAR4KDM4EGAARAB9A
SCHEMBL16958853 0.77 SLC6A4 (0.49) PLA2G2AFFAR4KDM4EGAARAB9A
SCHEMBL6383808 0.77 GAA (0.50) PLA2G2AFFAR4KDM4EGAARAB9A
SCHEMBL364074 0.76 FFAR4 (0.48) PLA2G2AMRGPRX4FFAR4KDM4EGAA
SCHEMBL7703503 0.76 FFAR4 (0.45) PLA2G2AFFAR4KDM4EGAARAB9A
SCHEMBL9938816 0.76 MAOB (0.50) PLA2G2AMRGPRX4FFAR4TAAR1MAOB
SCHEMBL2453770 0.74 SGMS2 (0.58) MRGPRX4FFAR4MAOBMAOAKDM4E
SCHEMBL21074369 0.74 L3MBTL1 (0.51) PLA2G2AFFAR4KDM4ERAB9AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023023594-A9 2‑DIARYLMETHYL‑4‑AMINOTETRAHYDROPYRAN DERIVATIVES AND RELATED COMPOUNDS AS ANTICANCER, ANTIINFLAMMATORY, ANTIFIBROTIC AND NEUROPROTECTIVE AGENTS ATUX ISKAY LLC (US) 2023-06-08 WO disclosed
US-20230146127-A1 3-DIARYLMETHYLENES AND USES THEREOF ATUX ISKAY LLC 2023-05-11 US disclosed
US-20230146127-A1 3-DIARYLMETHYLENES AND USES THEREOF ATUX ISKAY LLC 2023-05-11 US disclosed
WO-2023023594-A1 2‑DIARYLMETHYL‑4‑AMINOTETRAHYDROPYRAN DERIVATIVES AND RELATED COMPOUNDS AS ANTICANCER, ANTIINFLAMMATORY, ANTIFIBROTIC AND NEUROPROTECTIVE AGENTS ATUX ISKAY LLC (US) 2023-02-23 WO disclosed
WO-2021188949-A1 3-DIARYLMETHYLENES AND USES THEREOF ATUX ISKAY LLC (US) 2021-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230146127-A1 3-DIARYLMETHYLENES AND USES THEREOF MYC, MYCBP, FOXO1 PLA2G2A 4087/4885MRGPRX4 4688/4885FFAR4 4284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.